Kristi Miller
Adolescent Medicine · Opelika, ALNPI 1831794981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 26.3% of the total. 2025 is the largest year on record at $1,708, more than ten times the $33 reported in 2022. Among adolescent medicine clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $30.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$821
- Amgen$280
- GSK$267
- AbbVie$243
- Otsuka America Pharmaceutical, Inc.$198
- Lilly USA, LLC$193
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,120100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $821 |
| Amgen | 10 | $280 |
| GSK | 10 | $267 |
| AbbVie | 4 | $243 |
| Otsuka America Pharmaceutical, Inc. | 5 | $198 |
| Lilly USA, LLC | 5 | $193 |
| Novo Nordisk | 5 | $175 |
| Kowa Pharmaceuticals America, Inc. | 4 | $146 |
| Exact Sciences | 9 | $144 |
| Abbott | 1 | $128 |
| Neurocrine Biosciences, Inc. | 4 | $79 |
| Inspire Medical Systems, Inc. | 2 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Bayer | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 1 | $38 |
| Corcept Therapeutics | 2 | $37 |
| Medtronic | 1 | $27 |
| Pfizer | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,120 in reported general payments places this provider in the 90th percentile of 28 adolescent medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $109,036 |
| JardianceEmpagliflozin | 112 | $105,437 |
| MounjaroTirzepatide | 63 | $65,985 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $52,407 |
| FarxigaDapagliflozin Propanediol | 70 | $48,835 |
| KerendiaFinerenone | 36 | $26,432 |
| Repatha SyringeEvolocumab | 36 | $23,410 |
| RybelsusSemaglutide | 16 | $18,679 |
| EliquisApixaban | 25 | $17,176 |
| XareltoRivaroxaban | 13 | $13,509 |
| VascepaIcosapent Ethyl | 21 | $8,468 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,816 |
| Rosuvastatin Calcium | 275 | $5,432 |
| Atorvastatin Calcium | 405 | $5,124 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $175 | $127,715123 claims |
| Boehringer IngelheimJardiance | $18 | $105,437112 claims |
| Lilly USA, LLCMounjaro | $193 | $65,98563 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $267 | $57,05277 claims |
| AstraZenecaFarxiga, Symbicort | $821 | $54,65182 claims |
| BayerKerendia | $41 | $26,43236 claims |
| PfizerEliquis | $23 | $17,17625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 adolescent medicine providers in Alabama.
Other adolescent medicine in Opelika
- Ellen RoyalOpelika$903
- Richard FreemanOpelika$767
- Kristin RagerMobile$82K
- Fiona MastersDothan$6K
- Paul AmamooBirmingham$2K
- Bipin KumarWetumpka$2K
- Mary WellsMobile$1K
- Albert HollowayMontgomery$1K
- Debra GardnerMobile$1K
- James HarrellMobile$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.